On November 7, 2022 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, reported that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting (Press release, Affini-T Therapeutics, NOV 7, 2022, View Source [SID1234623295]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Patients are the central motivation for all of our work at Affini-T, and now is an exciting time to be in the KRAS drug development space – tackling hard-to-treat solid tumors for patients with high unmet needs," said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. "We have observed encouraging preclinical potency and selectivity data for our KRAS G12V TCR-T cell therapy candidates that support further clinical translation and development. We look forward to presenting our findings at the SITC (Free SITC Whitepaper) Conference in Boston."
Oral Presentation and Poster details are as follows:
Abstract #244 Oral presentation: Clinical Session 206 Nov 11th 12:10-1:10 pm ET (and poster presentation Nov 11th 11:55 am-1:25 pm and 7:00-8:30 pm ET): AFNT-111, a preclinically safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation – Presenting Author: Hubert Lam, Ph.D., Vice President, Preclinical Development, Affini-T Therapeutics
Abstract #342 Poster presentation: Nov 11th 11:55 am-1:25 pm and 7:00-8:30 pm ET: KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4/CD8 anti-tumor response in vitro and in vivo – Presenting Author: Gary Shapiro, Ph.D., Vice President, Discovery Biology, Affini-T Therapeutics